Presentation is loading. Please wait.

Presentation is loading. Please wait.

A decision matrix for readers, reviewers, and guideline makers to conceptualize results-based and process-based merits in clinical trials. A decision matrix.

Published byMagdalene Hubbard Modified over 5 years ago

Similar presentations

Presentation on theme: "A decision matrix for readers, reviewers, and guideline makers to conceptualize results-based and process-based merits in clinical trials. A decision matrix."— Presentation transcript:

1 A decision matrix for readers, reviewers, and guideline makers to conceptualize results-based and process-based merits in clinical trials. A decision matrix for readers, reviewers, and guideline makers to conceptualize results-based and process-based merits in clinical trials. Studies that have high results-based merit are characterized by narrow CIs and may or may not reject H0. Their level of acceptability, particularly in high impact journals, should be viewed through the lens of process-based merit. On the other hand, studies that are characterized by both low results-based and process-based merit are frequently rejected. Ajay K. Singh et al. CJASN 2008;3: ©2008 by American Society of Nephrology

Download ppt "A decision matrix for readers, reviewers, and guideline makers to conceptualize results-based and process-based merits in clinical trials. A decision matrix."

Similar presentations

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Mechanism by which negative sodium and water balance may improve myocardial and renal function in CHF. [Reprinted from J Am Coll Cardiol, vol. 47, Schrier.

Mechanism by which negative sodium and water balance may improve myocardial and renal function in CHF. [Reprinted from J Am Coll Cardiol, vol. 47, Schrier.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Conceptual model of the natural history of diabetic kidney disease.

Conceptual model of the natural history of diabetic kidney disease.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.

ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.
Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%

Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%
Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)
A glomerulus from a patient who developed nephrotic syndrome while receiving a nonsteroidal anti-inflammatory drug for arthritis. A glomerulus from a patient.

A glomerulus from a patient who developed nephrotic syndrome while receiving a nonsteroidal anti-inflammatory drug for arthritis. A glomerulus from a patient.

Similar presentations

Ads by Google